Skip to main content
BioMaxima S.A. logo

BioMaxima S.A. — Investor Relations & Filings

Ticker · BMX ISIN · PLBIOMX00015 LEI · 2594007GAALFMXP4YB89 WAR Manufacturing
Open in API
Filings indexed 616 across all filing types
Latest filing 2024-04-30 Audit Report / Informat…
Country PL Poland
Listing WAR BMX

About BioMaxima S.A.

https://www.biomaxima.com/

BioMaxima S.A. is a manufacturer specializing in in-vitro diagnostics. The company's primary activities include the development and production of a wide range of products for laboratory diagnostics, with a focus on clinical microbiology. Key product categories include microbiological media, various diagnostic reagents, and specialized laboratory equipment. In addition to its manufacturing operations, BioMaxima also serves as a distributor for products from other global diagnostics firms. The company is actively involved in product innovation, including the development of Minimum Inhibitory Concentration (MIC) tests for antibiotic susceptibility testing.

Recent filings

Filing Released Lang Actions
Jednostkowe sprawozdanie finansowe
Audit Report / Information Classification · 95% confidence The document text provided is an HTML structure containing CSS styling and font definitions, which is characteristic of a document that has been converted from a PDF format using a tool like pdf2htmlEX. The title tag reads 'BMX_JSF_2024-04-30_pl.xhtml'. The content itself is highly technical, related to rendering, and does not contain the narrative or structured financial data expected in a formal filing like a 10-K, IR, or ER. Given the nature of the input (a rendered HTML representation of a document, likely a regulatory filing or report, but the content itself is just the rendering structure), and the lack of specific financial keywords or regulatory headers (like 'Item 1.', 'Consolidated Balance Sheets', or 'Earnings Release'), this is most likely a generic container or a document that failed to render its primary content clearly in this snippet. However, the presence of a date (2024-04-30) and the structure suggest it is a specific report. Since the actual content is missing and only the rendering boilerplate is present, and the document length is very large (2.6M chars), it implies a substantial underlying document. Without content, the best classification is the fallback category for miscellaneous or unclassifiable regulatory documents. If this were a complete document, the structure might point towards a specific filing, but based *only* on the provided text (which is rendering code), it cannot be definitively classified as 10-K, IR, ER, etc. Therefore, I will use the Regulatory Filings fallback (RNS) as it covers miscellaneous filings that do not fit elsewhere, acknowledging the high uncertainty due to missing content. Q1 2024
2024-04-30 Polish
Skonsolidowane sprawozdanie finansowe
Annual Report Classification · 100% confidence The document is titled 'Skonsolidowane Sprawozdanie Finansowe 2023' which translates to 'Consolidated Financial Statement 2023'. It contains detailed consolidated financial statements for the year 2023 prepared according to International Financial Reporting Standards (IFRS) approved by the European Union. The content includes comprehensive financial data such as consolidated income statements, balance sheets, cash flow statements, notes to the financial statements, accounting policies, segment information, and other detailed disclosures. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The presence of full financial statements and detailed notes confirms this is a full annual financial report. Therefore, the document fits the definition of an Annual Report (10-K) rather than an announcement or a partial report. FY 2023
2024-04-30 Polish
Pismo Prezesa
Audit Report / Information Classification · 95% confidence The document text provided is extremely short (relative to the 590k character total length, but the provided snippet is mostly HTML/CSS structure from a PDF conversion tool like pdf2htmlEX) and consists primarily of boilerplate HTML structure, CSS styling, and metadata tags (like title: BMX_list_2023-12-31_pl.xhtml). There is no substantive financial content, regulatory headers (like 10-K, AR, ER), or specific reporting period details that would allow classification into a specific financial report type (10-K, IR, ER, etc.). Given the lack of content and the nature of the text being a conversion artifact, the most appropriate fallback category is 'Regulatory Filings' (RNS) as a general catch-all for unclassifiable regulatory documents, or potentially 'XLSX' if this was intended to be a data file, but RNS is safer for generic/unstructured regulatory output. FY 2023
2024-04-30 Polish
Pismo Prezesa
Audit Report / Information Classification · 95% confidence The document text provided is extremely short (relative to the 590k character total length, but the provided snippet is mostly HTML/CSS structure from a PDF conversion tool like pdf2htmlEX) and consists primarily of boilerplate HTML structure, CSS styling, and metadata tags (like title: BMX_list_2023-12-31_pl.xhtml). There is no substantive financial content, regulatory headers (like 10-K, AR, ER), or specific reporting period details that would allow classification into a specific financial report type (10-K, IR, ER, etc.). Given the lack of content and the nature of the text being a conversion artifact, the most appropriate fallback category is 'Regulatory Filings' (RNS) as a general catch-all for unclassifiable regulatory documents, or potentially 'XLSX' if this was intended to be a data file, but RNS is safer for generic/unstructured regulatory output. FY 2023
2024-04-30 Polish
Informacja o podpisaniu umowy o dofinansowanie w kwocie 4 824 793,35 zł - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a formal announcement by the Management Board (Zarząd) of BioMaxima SA regarding the signing of a co-financing agreement with PARP (Polish Agency for Enterprise Development) for an R&D project related to molecular diagnostic kits (qPCR and LAMP). It details the amount of funding (4,824,793.35 PLN), the project scope (developing Salmonella and Listeria detection kits), and mentions that this follows up on a previous current report (Raport bieżący nr 30/2023). This type of announcement, detailing significant financing, R&D milestones, or material contracts, fits best under 'Capital/Financing Update' (CAP) as it directly concerns the company's funding and development activities, or potentially 'Regulatory Filings' (RNS) if it were a general regulatory disclosure. Given the specific focus on securing a large grant/co-financing for a strategic project, CAP is the most precise fit among the provided options, as it relates to capital structure/fundraising activities, even if it's grant-based.
2024-02-05 Polish
Terminy przekazywania raportów okresowych w 2024 roku - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text explicitly states the schedule ('terminy przekazywania') for the release of periodic reports ('raportów okresowych') for the fiscal year 2024, including dates for the full-year 2023 report, Q1 2024 report, H1 2024 report, and Q3 2024 report. It also mentions where these reports will be published (company website) and cites the relevant Polish financial regulation (§ 80 ust. 1 Rozporządzenia Ministra Finansów). Since the document is an announcement detailing *when* reports will be released, rather than the reports themselves, it fits the definition of a Report Publication Announcement (RPA). The document length (1270 chars) is very short, supporting the RPA classification over the actual periodic reports (like IR or 10-K).
2024-01-26 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.